BioWorld

March 13, 2002

Myriad, Abbott Team In Deal To Diagnose, Treat Depression

Myriad Genetics Inc. entered a deal worth upward of $34 million with Abbott Laboratories Inc. to identify genes and drug targets for the diagnosis and treatment of depression. (BioWorld Today) Read More

Ricerca Licenses Cancer Gene; CRO Embraces New Paradigm’

Classic Mutant Mouse With Multi- Neuronal Disorders Shines Light On Potential Human Manipulation

Alexion, CuraGen Seek Cancer Targets For Drug Development

Phenomix’s Forward Genetics’ Gets $32M Funding Commitment

Other News To Note

Senomyx Raises $36.8M Privately To Fund Taste, Smell Programs

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...